Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches

References

• Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011 Jun;40(6):539–546.
   PubMed Web of Science ®Google Scholar
• de St. Aubain Somerhausen N, de Rijn M V. Tenosynovial giant cell tumour. In: The WHO Classification of Tumours Editorial Board, editor. 5th World Health Organization Classification Of Tumours Of Soft Tissue And Bone. Lyon:IARC Press.2020.
   Google Scholar
• Mastboom MJL, Verspoor FGM, Hanff DF, et al. Severity classification of tenosynovial giant cell tumours on MR imaging. Surg Oncol. 2018 Sep;27(3):544–550.
   PubMed Web of Science ®Google Scholar
• Rubin BP. Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions. Skeletal Radiol. 2007 Apr;36(4):267–268.
   PubMed Web of Science ®Google Scholar
• Sansone V, Longhino V. What’s in a name? A call for consistency in the classification of tenosynovial giant cell tumour. Knee. 2018 Dec;25(6):1322–1323.
   PubMed Web of Science ®Google Scholar
• Ehrenstein V, Andersen SL, Qazi I, et al. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in denmark. J Rheumatol. 2017 Oct;44(10):1476–1483.
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017 Dec;88(6):688–694.
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Verspoor FGM, Uittenbogaard D, et al. tenosynovial giant cell tumors in children: a similar entity compared with adults. Clin Orthop Relat Res. 2018 Sep;476(9):1803–1812.
   PubMedGoogle Scholar
• Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017 Feb;103(1s):S91–s97.
   PubMedGoogle Scholar
• Gelhorn HL, Tong S, McQuarrie K, et al. Patient-reported symptoms of tenosynovial giant cell tumors. Clin Ther. 2016 Apr;38(4):778–793.
   PubMed Web of Science ®Google Scholar
• Bernthal NM, Spierenburg G, Healey JH, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. Orphanet J Rare Dis. 2021 Apr 29;16(1):191.
   PubMed Web of Science ®Google Scholar
• van der Heijden L, Mastboom MJ, Dijkstra PD, et al. Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients. Bone Joint J. 2014 Aug;96-b(8):1111–1118.
   PubMed Web of Science ®Google Scholar
• Verspoor FGM, Mastboom MJL, Hannink G, et al. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. Bone Joint J. 2019 Mar;101-b(3):272–280.
   PubMedGoogle Scholar
• Lopez-Bastida J, Aranda-Reneo I, Rodríguez-Sánchez B, et al. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. Orphanet J Rare Dis. 2021 Jul 2;16(1):294.
   PubMed Web of Science ®Google Scholar
• Murphey MD, Rhee JH, Lewis RB, et al. Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics. 2008 Sep-Oct;28(5):1493–1518.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Tsukushi S, Nakashima H, et al. Osteochondral destruction in pigmented villonodular synovitis during the clinical course. J Rheumatol. 2012 Feb;39(2):345–351.
   PubMed Web of Science ®Google Scholar
• Jaffe HL, Lichtenstein L, Sutro CJ. Pigmented villonodular synovitis, bursitis and tenosynovitis. Arch Pathol. 1941;31:731–765.
   Google Scholar
• Dal Cin P, Sciot R, Samson I, et al. Cytogenetic characterization of tenosynovial giant cell tumors (nodular tenosynovitis). Cancer Res. 1994 Aug 1;54(15):3986–3987.
   PubMed Web of Science ®Google Scholar
• Sciot R, Rosai J, Dal Cin P, et al. Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group. Mod Pathol. 1999 Jun;12(6):576–579.
   PubMed Web of Science ®Google Scholar
• West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690–695.
   PubMed Web of Science ®Google Scholar
• Stanley ER, Berg KL, Einstein DB, et al. Biology and action of colony–stimulating factor-1. Mol Reprod Dev. 1997 Jan;46(1):4–10.
   PubMed Web of Science ®Google Scholar
• Barreda DR, Hanington PC, Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol. 2004 May 3;28(5):509–554.
   PubMed Web of Science ®Google Scholar
• Nilsson M, Höglund M, Panagopoulos I, et al. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors. Virchows Arch. 2002 Nov;441(5):475–480.
   PubMed Web of Science ®Google Scholar
• Möller E, Mandahl N, Mertens F, et al. Molecular identification of COL6A3‐CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2008;47(1):21–25.
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Brandal P, Gorunova L, et al. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors. Int J Oncol. 2014 May;44(5):1425–1432.
   PubMed Web of Science ®Google Scholar
• Cupp JS, Miller MA, Montgomery KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007 Jun;31(6):970–976.
   PubMed Web of Science ®Google Scholar
• Brahmi M, Alberti L, Tirode F, et al. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene. Ann Oncol. 2018 Jun 1;29(6):1488–1489.
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Hirata M, Katayama K, et al. Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. Int J Cancer. 2019 Dec 15;145(12):3276–3284.
   PubMed Web of Science ®Google Scholar
• Ho J, Peters T, Dickson BC, et al. Detection of CSF1 rearrangements deleting the 3ʹUTR in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2019 Aug 30; 59(2):96–105.
   PubMed Web of Science ®Google Scholar
• Vougiouklakis T, Shen G, Feng X, et al. Molecular profiling of atypical tenosynovial giant cell tumors reveals novel non-CSF1 fusions. Cancers (Basel). 2019 Dec 31;12(1):100.
   Web of Science ®Google Scholar
• Ota T, Urakawa H, Kozawa E, et al. Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis. Tumor Biology. 2015 Jul;36(7):5361–5367.
   PubMedGoogle Scholar
• Mastboom MJL, Hoek DM, Bovee J, et al. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Histopathology. 2019 Jan;74(2):332–340.
   PubMed Web of Science ®Google Scholar
• Finis K, Sültmann H, Ruschhaupt M, et al. Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches. Arthritis Rheum. 2006 Mar;54(3):1009–1019.
   PubMedGoogle Scholar
• Darling JM, Goldring SR, Harada Y, et al. Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. Am J Pathol. 1997 Apr;150(4):1383–1393.
   PubMed Web of Science ®Google Scholar
• Somerhausen NS, Fletcher CD. Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease. Am J Surg Pathol. 2000 Apr;24(4):479–492.
   PubMed Web of Science ®Google Scholar
• Yoshida W, Uzuki M, Kurose A, et al. Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis. Hum Pathol. 2003 Jan;34(1):65–73.
   PubMed Web of Science ®Google Scholar
• Boland JM, Folpe AL, Hornick JL, et al. Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications. Am J Surg Pathol. 2009 Aug;33(8):1225–1229.
   PubMed Web of Science ®Google Scholar
• O’Connell JX, Fanburg JC, Rosenberg AE. Giant cell tumor of tendon sheath and pigmented villonodular synovitis: immunophenotype suggests a synovial cell origin. Hum Pathol. 1995 Jul;26(7):771–775.
   PubMed Web of Science ®Google Scholar
• Ding Y, Griffin JE, Raghavan M, et al. Tenosynovial giant cell tumors lacking giant cells: report of diagnostic pitfalls. Ann Clin Lab Sci Spring. 2014;44(2):222–227.
   PubMed Web of Science ®Google Scholar
• Cao C, Wu F, Niu X, et al. Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis. Theranostics. 2020;10(23):10573–10588.
   PubMed Web of Science ®Google Scholar
• Li CF, Wang JW, Huang WW, et al. Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature. Am J Surg Pathol. 2008 Apr;32(4):587–599.
   PubMed Web of Science ®Google Scholar
• Al-Ibraheemi A, Ahrens WA, Fritchie K, et al. Malignant tenosynovial giant cell tumor: the true “synovial sarcoma?” A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes. Mod Pathol. 2019 Feb;32(2):242–251.
   PubMed Web of Science ®Google Scholar
• Aurégan JC, Klouche S, Bohu Y, et al. Treatment of pigmented villonodular synovitis of the knee. Arthroscopy: J Arthroscopic & Related Surgery: Off publArthroscopy Assoc North Am Int Arthroscopy Assoc. 2014 Oct;30(10):1327–1341.
   PubMed Web of Science ®Google Scholar
• Noailles T, Brulefert K, Briand S, et al. Giant cell tumor of tendon sheath: open surgery or arthroscopic synovectomy? A systematic review of the literature. Orthopaedics & Traumatology: Surgery & Research. 2017 Sep;103(5):809–814.
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Staals EL, Verspoor FGM, et al. Surgical treatment of localized-type tenosynovial giant cell tumors of large joints: a study based on a multicenter-pooled database of 31 International Sarcoma Centers. J Bone Joint Surg Am Vol. 2019 Jul 17;101(14):1309–1318.
   PubMedGoogle Scholar
• Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019 Apr 24;20:877–886.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Maki RG, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. Eur J Cancer. 2015 Jan;51(2):210–217.
   PubMed Web of Science ®Google Scholar
• Healey JH, Bernthal NM, van de Sande M. Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease. J Am Acad Orthop Surg Glob Res Rev. 2020 Nov;4(11):e2000028.
   Google Scholar
• Staals EL, Ferrari S, Donati DM, et al. Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives. Eur J Cancer. 2016 Aug;63:34–40.
   PubMed Web of Science ®Google Scholar
• van der Heijden L, Gibbons CL, Hassan AB, et al. A multidisciplinary approach to giant cell tumors of tendon sheath and synovium–a critical appraisal of literature and treatment proposal. J Surg Oncol. 2013 Mar;107(4):433–445.
   PubMed Web of Science ®Google Scholar
• Griffin AM, Ferguson PC, Catton CN, et al. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery. Cancer. 2012 Oct 1;118(19):4901–4909.
   PubMed Web of Science ®Google Scholar
• Durr HR, Capellen CF, Klein A, et al. The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee. Arch Orthop Trauma Surg. 2019 May;139(5):623–627.
   PubMed Web of Science ®Google Scholar
• Gortzak Y, Vitenberg M, Frenkel Rutenberg T, et al. Inconclusive benefit of adjuvant (90)Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee. Bone Joint J. 2018 Jul;100-b(7):984–988.
   PubMedGoogle Scholar
• Bickels J, Isaakov J, Kollender Y, et al. Unacceptable complications following intra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J Bone Joint Surg Am Vol. 2008 Feb;90(2):326–328.
   PubMedGoogle Scholar
• Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. 2015 Apr;97-b(4):550–557.
   PubMed Web of Science ®Google Scholar
• Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018 Jun;36(2):85–94.
   PubMed Web of Science ®Google Scholar
• Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008 Apr;19(4):821–822.
   PubMed Web of Science ®Google Scholar
• Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Hum Cell. 2020 Sep 4;34:254–259.
   PubMed Web of Science ®Google Scholar
• Tang F, Tie Y, Hong WQ, et al. Patient-derived tumor xenografts plus ex vivo models enable drug validation for tenosynovial giant cell tumors. Ann Surg Oncol. 2021 Mar 21;28:6453–6463.
   PubMed Web of Science ®Google Scholar
• Brahmi M, Vinceneux A, Cassier PA. Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol. 2016 Feb;17(2):10.
   PubMed Web of Science ®Google Scholar
• Liang J, Zhao W, Tong P, et al. Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer. BMC Med Genomics. 2020 Jan 21;13(1):7.
   PubMed Web of Science ®Google Scholar
• Ding Z, Bai Z, Zhang M, et al. cIAP2 expression and clinical significance in pigmented villonodular synovitis. J Mol Histol. 2021 Feb 18;52:397–406.
   PubMed Web of Science ®Google Scholar
• Cao C, Zhang Y, Cheng J, et al. β-Arrestin2 inhibits the apoptosis and facilitates the proliferation of fibroblast-like synoviocytes in diffuse-type tenosynovial giant cell tumor. Cancer Genomics Proteomics. 2021 May-Jun;18(3 Suppl):461–470.
   PubMed Web of Science ®Google Scholar
• Rosen ED, Hsu CH, Wang X, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002 Jan 1;16(1):22–26.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Yamamoto N, Nishida H, et al. Complete necrosis of a giant cell tumor with high expression of PPARγ: a case report. Anticancer Res. 2013 May;33(5):2169–2174.
   PubMed Web of Science ®Google Scholar
• O’Keefe RJ, Rosier RN, Teot LA, et al. Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J. 1998;18:26–34.
   PubMedGoogle Scholar
• Fiocco U, Sfriso P, Lunardi F, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis. Autoimmun Rev. 2010 Sep;9(11):780–784.
   PubMed Web of Science ®Google Scholar
• Curry JM, Eubank TD, Roberts RD, et al. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PloS one. 2008;3(10):e3405.
   PubMed Web of Science ®Google Scholar
• Yamagishi T, Kawashima H, Ogose A, et al. Expression profiling of receptor-activator of nuclear factor-kappa b ligand in soft tissue tumors. Tohoku J Exp Med. 2019 Jun;248(2):87–97.
   PubMed Web of Science ®Google Scholar
• Palmerini E, Chawla NS, Ferrari S, et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer. 2017 May;76:118–124.
   PubMed Web of Science ®Google Scholar
• Feng W, Guo J, Li M. RANKL-independent modulation of osteoclastogenesis. J Oral Biosci. 2019 Mar;61(1):16–21.
   PubMed Web of Science ®Google Scholar
• van der Heijden L, Gibbons CL, Dijkstra PD, et al. The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). J Bone Joint Surg Br. 2012 Jul;94(7):882–888.
   PubMedGoogle Scholar
• Zheng B, Yu L, Hu J, et al. Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors. Int J Clin Exp Pathol. 2019;12(3):876–884.
   PubMed Web of Science ®Google Scholar
• Hutarew G. PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view. Memo. 2016;9(4):201–206.
   PubMedGoogle Scholar
• Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012 Mar 15;118(6):1649–1655.
   PubMed Web of Science ®Google Scholar
• Verspoor FGM, Mastboom MJL, Hannink G, et al. Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Sci Rep. 2019 Oct 10;9(1):14551.
   PubMed Web of Science ®Google Scholar
• Mastboom MJL, Lips W, van Langevelde K, et al. The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT. Surg Oncol. 2020 Aug 26;35:261–267.
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Crippa F, Messina A, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013 May 13;3(1):8.
   PubMedGoogle Scholar
• Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846–859.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949–956.
   PubMed Web of Science ®Google Scholar
• Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer. 2020 Nov 5;141:162–170.
   PubMed Web of Science ®Google Scholar
• Smart K, Bröske AM, Rüttinger D, et al. PK/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse-type tenosynovial giant cell tumor. Clin Pharmacol Ther. 2020 Jun 23;108:616–624.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018 May;19(5):639–648.
   PubMed Web of Science ®Google Scholar
• Monestime S, Lazaridis DP. (TURALIO™): the First FDA-Indicated systemic treatment for tenosynovial giant cell tumor. Drugs R D. 2020 Sep;20(3):189–195.
   PubMed Web of Science ®Google Scholar
• Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015 Jul 30;373(5):428–437.
   PubMed Web of Science ®Google Scholar
• Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Jun 19;394:478–487.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Wagner AJ, Tap WD, et al. Long-term outcomes of pexidartinib in tenosynovial giant cell tumors. Cancer. 2020 Nov 16;127(6):884–893.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Gelderblom H, van de Sande M, et al. Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors. Oncologist. 2021 May;26(5):e863–e73.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, de Sande MV. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncol. 2020 Jul 23;16:2345–2356.
   PubMed Web of Science ®Google Scholar
• Cheng E, Kudlidjian A, Block J MCS110, an anti-CSF-1 antibody, for the treatment of pigmented villonodular synovitis (PVNS). ISOLS/MSTS 2015 Annual Meeting, Orlando, Florida: 2015.
   Google Scholar
• Sankhala KK, Blay J-Y, Ganjoo KN, et al. A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS). J clin oncol. 2017;35(15_suppl):11078.
   Google Scholar
• Smith BD, Kaufman MD, Wise SC, et al. Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages. Mol Cancer Ther. 2021 Aug 25;20:2098–2109.
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Razak ARA, Sanchez-Gastaldo A, et al. Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT). ESMO Congress. 2021 September 16-21;32(supplement 5):S1233–S1234. https://doi.org/https://doi.org/10.1016/j.annonc.2021.08.275
   Google Scholar
• Kroot EJ, Kraan MC, Smeets TJ, et al. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis. 2005 Mar;64(3):497–499.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee. Reumatismo. 2006 Oct-Dec;58(4):268–274.
   PubMedGoogle Scholar
• Eubank TD, Galloway M, Montague CM, et al. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003 Sep 1;171(5):2637–2643.
   PubMed Web of Science ®Google Scholar
• Nissen MJ, Boucher A, Brulhart L, et al. Efficacy of intra-articular bevacizumab for relapsing diffuse-type giant cell tumour. Ann Rheum Dis. 2014 May;73(5):947–948.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Nomura A, Yamamoto N, et al. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol. BMC Musculoskelet Disord. 2019 Feb 9;20(1):68.
   PubMedGoogle Scholar
• An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee. [ cited 2021 Nov 01]. Available from: https://ClinicalTrials.gov/show/NCT04731675
   Google Scholar
• Study to evaluate discontinuation and re-treatment in participants with Tenosynovial Giant Cell Tumor (TGCT). Previously Treated With Pexidartinib. [cited 2021 Nov 01]. Available from: https://ClinicalTrials.gov/show/NCT04526704
   Google Scholar
• Kasper B. The challenge of drug approval in rare cancers. Cancer. 2020 Nov 16;127(6): 837–839.
   PubMed Web of Science ®Google Scholar